Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Famotidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.95 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.95 |
| ▸ | CA12 | O43570 | 2/20 | 0.95 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.95 |
| ▸ | CA2 | P00918 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | MAOA | P21397 | 2/20 | 0.95 |
| ▸ | CA4 | P22748 | 2/20 | 0.95 |
| ▸ | CA6 | P23280 | 2/20 | 0.95 |
| ▸ | CA5A | P35218 | 2/20 | 0.95 |
| ▸ | CA7 | P43166 | 2/20 | 0.95 |
| ▸ | BLM | P54132 | 2/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.95 |
| ▸ | POU5F1 | Q01860 | 2/20 | 0.95 |
| ▸ | CA9 | Q16790 | 2/20 | 0.95 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.95 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.95 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famotidine SCHEMBL458654 | 0.98 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL39237 | 0.98 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL29384901 | 0.98 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL973 | 0.98 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28032679 | 0.97 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863201 | 0.97 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL22127098 | 0.97 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL7119657 | 0.95 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28528271 | 0.95 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL9817308 | 0.95 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | claimed |
| CN-114903850-A | Famotidine hydrochloride sustained-release suspension preparation and preparation method thereof | 江苏大学 | 2022-08-16 | — | — | CN | claimed |
| WO-2021183259-A1 | FAMOTIDINE AND FAMOTIDINE ANALOGS FOR CORONA VIRUS TREATMENT | Nanopharmaceutics, Inc. (US) | 2021-09-16 | — | — | WO | claimed |
| US-20030230530-A1 | Process for the preparation of a combination of Famotidine Polymorphs A and B | M/S. TONIRA PHARMA LIMITED (IN) | 2003-12-18 | — | — | US | claimed |
| EP-1361221-A1 | A process for the preparation of a combination of famotidine polymorphs A and B | M/s. TONIRA PHARMA LIMITED (IN) | 2003-11-12 | — | — | EP | claimed |
| EP-0297019-B1 | FAMOTIDINE POLYMORPHIC FORM AND PREPARATION THEREOF | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1991-10-30 | — | — | EP | claimed |
| CN-112585283-B | Method for distinguishing live microorganism from dead microorganism in sample | 帕特霍奎斯特公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4491197-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL TABLET, AND METHOD FOR MANUFACTURING SAME | Mitsubishi Chemical Corporation (JP) | 2025-01-15 | — | — | EP | disclosed |
| CN-116249720-B | Detoxified Lipopolysaccharide (LPS), natural non-toxic LPS and its use | 赫菲斯托斯制药公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-119013042-A | Companion diagnosis of human CEACAM1 targeted therapeutics | 布里格姆及妇女医院股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118973560-A | Compounds for the treatment of dystrophin | 索姆创新生物技术公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240165086-A1 | COATED FAMOTIDINE PARTICLE | KENVUE BRANDS LLC | 2024-05-23 | — | — | US | disclosed |
| CN-117580567-A | Pharmaceutical composition comprising famotidine | 强生消费者公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-1994014750-A1 | NOVEL SALICYLIC ACID DERIVATIVES, THEIR SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1994-07-07 | — | — | WO | disclosed |
| CN-1074440-A | Gastric acid secretion inhibiting and gastric cell protecting pharmaceutical composition, novel famotidine salt and preparation method thereof | RICHTER GEDEON VEGYESZET (HU) | 1993-07-21 | — | — | CN | disclosed |
| WO-1993013076-A1 | GASTRIC ACID SECRETION-INHIBITING, AND GASTROCYTOPROTECTIVE PHARMACEUTICAL COMPOSITIONS, NOVEL FAMOTIDINE SALTS AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1993-07-08 | — | — | WO | disclosed |
| EP-0297019-B1 | FAMOTIDINE POLYMORPHIC FORM AND PREPARATION THEREOF | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1991-10-30 | — | — | EP | disclosed |
| US-5021582-A | Acidifying alcoholic suspension, adding organic base, heating, diluting with chlorinated hydrrocarbon, cooling, filtering | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1991-06-04 | — | — | US | disclosed |
| EP-0322335-A1 | New-quanidino-thiazol compounds, their preparation, and use as intermediates of famotidine process | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1989-06-28 | — | — | EP | disclosed |
| EP-0297019-A1 | Famotidine polymorphic form and preparation thereof | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1988-12-28 | — | — | EP | disclosed |